Bactine Max Antibiotic And Lidocaine Max Pain Relief Ointment
NDC Package 65197-827-05
Package Information
Bactine Max Antibiotic And Lidocaine Max Pain Relief (lidocaine) ointment is a medication used to help reduce itching and pain from certain skin conditions (such as scrapes, minor skin irritations, insect bites). This formulation utilizes a ointment delivery system. Marketed by Wellspring Pharmaceutical Corporation, this product is identified by NDC 65197-827 and is authorized under FDA application M017.
Identification & Billing
Clinical Specifications
- Amide Local Anesthetic - [EPC] (Established Pharmacologic Class)
- Amides - [CS]
- Antiarrhythmic - [EPC] (Established Pharmacologic Class)
- Decreased Cell Wall Synthesis & Repair - [PE] (Physiologic Effect)
- Local Anesthesia - [PE] (Physiologic Effect)
- Polymyxin-class Antibacterial - [EPC] (Established Pharmacologic Class)
- Polymyxins - [CS]
Regulatory & Marketing
Hierarchy Structure
- 65197 - Wellspring Pharmaceutical Corporation
- 65197-827 - Bactine Max Antibiotic And Lidocaine Max Pain Relief
- 65197-827-05 - 1 TUBE in 1 BOX / 14.2 g in 1 TUBE
- 65197-827 - Bactine Max Antibiotic And Lidocaine Max Pain Relief
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 65197-827-05 identifies a specific commercial package of 1 tube in 1 box / 14.2 g in 1 tube of Bactine Max Antibiotic And Lidocaine Max Pain Relief, a human over the counter drug labeled by Wellspring Pharmaceutical Corporation. This ointment is formulated for topical use and contains bacitracin zinc; lidocaine hydrochloride; polymyxin b sulfate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Wellspring Pharmaceutical Corporation on January 15, 2024. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This product is used to help reduce itching and pain from certain skin conditions (such as scrapes, minor skin irritations, insect bites). It may also be used to help relieve nerve pain after shingles (infection with herpes zoster virus). Lidocaine belongs to a class of drugs known as local anesthetics. It works by causing a temporary loss of feeling in the area where you apply the patch.
How is this Wellspring Pharmaceutical Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 65197082705. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.